| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abnormal Structure of Cerebral White and Cortical Gray Matter in Preclinical Huntington’s Disease
|
Nopoulos, P.
|
|
2008
|
5 |
2 |
p. 369-370
2 p.
|
artikel
|
| 2 |
Abnormal Structure of Cerebral White and Cortical Gray Matter in Preclinical Huntington’s Disease
|
Nopoulos, P.
|
|
|
5 |
2 |
p. 369-370
|
artikel
|
| 3 |
Abstract withdrawn
|
|
|
2008
|
5 |
2 |
p. 364-
1 p.
|
artikel
|
| 4 |
Abstract withdrawn
|
|
|
|
5 |
2 |
p. 364
|
artikel
|
| 5 |
A Comparison of Two Brief Cognitive Screening Instruments in Huntington Disease (HD)
|
Mickes, L.
|
|
2008
|
5 |
2 |
p. 373-
1 p.
|
artikel
|
| 6 |
A Comparison of Two Brief Cognitive Screening Instruments in Huntington Disease (HD)
|
Mickes, L.
|
|
|
5 |
2 |
p. 373
|
artikel
|
| 7 |
Advanced therapies for movement disorders in neurotherapeutics
|
Delong, Mahlon R.
|
|
2008
|
5 |
2 |
p. 163
|
artikel
|
| 8 |
Advanced Therapies for Movement Disorders in Neurotherapeutics
|
Delong, Mahlon R.
|
|
2008
|
5 |
2 |
p. 163-
1 p.
|
artikel
|
| 9 |
Advanced Therapies for Movement Disorders in Neurotherapeutics
|
Delong, Mahlon R.
|
|
|
5 |
2 |
p. 163
|
artikel
|
| 10 |
Advances in gene therapy for movement disorders
|
Mochizuki, Hideki
|
|
2008
|
5 |
2 |
p. 260-269
|
artikel
|
| 11 |
Advances in Gene Therapy for Movement Disorders
|
Mochizuki, Hideki
|
|
2008
|
5 |
2 |
p. 260-269
10 p.
|
artikel
|
| 12 |
Advances in Gene Therapy for Movement Disorders
|
Mochizuki, Hideki
|
|
|
5 |
2 |
p. 260-269
|
artikel
|
| 13 |
A Model of the Extent and Impact of Inter-Rater Variability for the UHDRS Motor and Diagnostic Confidence Scales
|
Langbehn, D.R.
|
|
2008
|
5 |
2 |
p. 372-
1 p.
|
artikel
|
| 14 |
A Model of the Extent and Impact of Inter-Rater Variability for the UHDRS Motor and Diagnostic Confidence Scales
|
Langbehn, D.R.
|
|
|
5 |
2 |
p. 372
|
artikel
|
| 15 |
A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease: 12-Month Results
|
Dorsey, E.R.
|
|
2008
|
5 |
2 |
p. 363-
1 p.
|
artikel
|
| 16 |
A Randomized, Controlled Trial of Ethyl-EPA for the Treatment of Huntington Disease: 12-Month Results
|
Dorsey, E.R.
|
|
|
5 |
2 |
p. 363
|
artikel
|
| 17 |
A Review of the Use of Concomitant Medication for Huntington’s Disease in Europe Between 2004 and 2007 Based on the European HD REGISTRY
|
Priller, J.
|
|
2008
|
5 |
2 |
p. 375-
1 p.
|
artikel
|
| 18 |
A Review of the Use of Concomitant Medication for Huntington’s Disease in Europe Between 2004 and 2007 Based on the European HD REGISTRY
|
Priller, J.
|
|
|
5 |
2 |
p. 375
|
artikel
|
| 19 |
A Scale To Measure Quality of Life in Huntington’s Disease Spousal Carers
|
Aubeeluck, A.
|
|
2008
|
5 |
2 |
p. 371-
1 p.
|
artikel
|
| 20 |
A Scale To Measure Quality of Life in Huntington’s Disease Spousal Carers
|
Aubeeluck, A.
|
|
|
5 |
2 |
p. 371
|
artikel
|
| 21 |
Assessment of Inattention and Executive Dysfunction in Early Huntington’s Disease: The Atomoxetine Pilot Trial
|
Beglinger, L.J.
|
|
2008
|
5 |
2 |
p. 375-
1 p.
|
artikel
|
| 22 |
Assessment of Inattention and Executive Dysfunction in Early Huntington’s Disease: The Atomoxetine Pilot Trial
|
Beglinger, L.J.
|
|
|
5 |
2 |
p. 375
|
artikel
|
| 23 |
A Study in Pre-Manifest Huntington’s Disease of Coenzyme Q10 (Ubiquinone)
|
Biglan, K.M.
|
|
2008
|
5 |
2 |
p. 367-368
2 p.
|
artikel
|
| 24 |
A Study in Pre-Manifest Huntington’s Disease of Coenzyme Q10 (Ubiquinone)
|
Biglan, K.M.
|
|
|
5 |
2 |
p. 367-368
|
artikel
|
| 25 |
Brain Correlates of Neuropsychological Function in Presymptomatic HD Gene Carriers
|
Mattis, P.
|
|
2008
|
5 |
2 |
p. 366-
1 p.
|
artikel
|
| 26 |
Brain Correlates of Neuropsychological Function in Presymptomatic HD Gene Carriers
|
Mattis, P.
|
|
|
5 |
2 |
p. 366
|
artikel
|
| 27 |
Break and poster viewing
|
|
|
2008
|
5 |
2 |
p. 363-
1 p.
|
artikel
|
| 28 |
Break and poster viewing
|
|
|
|
5 |
2 |
p. 363
|
artikel
|
| 29 |
Candidates for Neurocognitive Markers in PRE-HD: Longitudinal Assessment From the PREDICT-HD COHORT
|
Stout, J.C.
|
|
2008
|
5 |
2 |
p. 372-
1 p.
|
artikel
|
| 30 |
Candidates for Neurocognitive Markers in PRE-HD: Longitudinal Assessment From the PREDICT-HD COHORT
|
Stout, J.C.
|
|
|
5 |
2 |
p. 372
|
artikel
|
| 31 |
COHORT: A Snapshot of Baseline Characteristics
|
Chirieac, M.C.
|
|
2008
|
5 |
2 |
p. 365-
1 p.
|
artikel
|
| 32 |
COHORT: A Snapshot of Baseline Characteristics
|
Chirieac, M.C.
|
|
|
5 |
2 |
p. 365
|
artikel
|
| 33 |
Communicating Findings to Research Participants: Preliminary Results from the TREND-HD Study
|
Dorsey, E.R.
|
|
2008
|
5 |
2 |
p. 374-375
2 p.
|
artikel
|
| 34 |
Communicating Findings to Research Participants: Preliminary Results from the TREND-HD Study
|
Dorsey, E.R.
|
|
|
5 |
2 |
p. 374-375
|
artikel
|
| 35 |
Contents
|
|
|
2008
|
5 |
2 |
p. A2-A4
nvt p.
|
artikel
|
| 36 |
Contents
|
|
|
|
5 |
2 |
p. A2-A4
|
artikel
|
| 37 |
Controlling for Individual Differences in Neurocognitive Markers in Pre-Diagnosis HD in the PREDICT-HD Cohort
|
Stout, J.C.
|
|
2008
|
5 |
2 |
p. 373-
1 p.
|
artikel
|
| 38 |
Controlling for Individual Differences in Neurocognitive Markers in Pre-Diagnosis HD in the PREDICT-HD Cohort
|
Stout, J.C.
|
|
|
5 |
2 |
p. 373
|
artikel
|
| 39 |
Correction of Brain Atrophy in Metabolic Imaging of Presymptomatic Huntington’s Disease: A Combined FDG PET and MRI Study
|
Ma, Y.
|
|
2008
|
5 |
2 |
p. 366-367
2 p.
|
artikel
|
| 40 |
Correction of Brain Atrophy in Metabolic Imaging of Presymptomatic Huntington’s Disease: A Combined FDG PET and MRI Study
|
Ma, Y.
|
|
|
5 |
2 |
p. 366-367
|
artikel
|
| 41 |
Current status of symptomatic medical therapy in Parkinson’s disease
|
Factor, Stewart A.
|
|
2008
|
5 |
2 |
p. 164-180
|
artikel
|
| 42 |
Current Status of Symptomatic Medical Therapy in Parkinson’s Disease
|
Factor, Stewart A.
|
|
2008
|
5 |
2 |
p. 164-180
17 p.
|
artikel
|
| 43 |
Current Status of Symptomatic Medical Therapy in Parkinson’s Disease
|
Factor, Stewart A.
|
|
|
5 |
2 |
p. 164-180
|
artikel
|
| 44 |
Deep brain stimulation and tremor
|
Lyons, Kelly E.
|
|
2008
|
5 |
2 |
p. 331-338
|
artikel
|
| 45 |
Deep Brain Stimulation and Tremor
|
Lyons, Kelly E.
|
|
2008
|
5 |
2 |
p. 331-338
8 p.
|
artikel
|
| 46 |
Deep Brain Stimulation and Tremor
|
Lyons, Kelly E.
|
|
|
5 |
2 |
p. 331-338
|
artikel
|
| 47 |
Deep brain stimulation for Parkinson’s disease
|
Limousin, Patricia
|
|
2008
|
5 |
2 |
p. 309-319
|
artikel
|
| 48 |
Deep Brain Stimulation for Parkinson’s Disease
|
Limousin, Patricia
|
|
2008
|
5 |
2 |
p. 309-319
11 p.
|
artikel
|
| 49 |
Deep Brain Stimulation for Parkinson’s Disease
|
Limousin, Patricia
|
|
|
5 |
2 |
p. 309-319
|
artikel
|
| 50 |
Deep brain stimulation in Tourette’s syndrome
|
Ackermans, Linda
|
|
2008
|
5 |
2 |
p. 339-344
|
artikel
|
| 51 |
Deep Brain Stimulation in Tourette’s Syndrome
|
Ackermans, Linda
|
|
2008
|
5 |
2 |
p. 339-344
6 p.
|
artikel
|
| 52 |
Deep Brain Stimulation in Tourette’s Syndrome
|
Ackermans, Linda
|
|
|
5 |
2 |
p. 339-344
|
artikel
|
| 53 |
Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease
|
Patzke, H.
|
|
2008
|
5 |
2 |
p. 371-
1 p.
|
artikel
|
| 54 |
Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease
|
Patzke, H.
|
|
|
5 |
2 |
p. 371
|
artikel
|
| 55 |
Editorial Board
|
|
|
2008
|
5 |
2 |
p. A1-
1 p.
|
artikel
|
| 56 |
Editorial Board
|
|
|
|
5 |
2 |
p. A1
|
artikel
|
| 57 |
Emerging Clinical Candidates From the CHDI Pipeline
|
Pacifici, Robert
|
|
2008
|
5 |
2 |
p. 363-
1 p.
|
artikel
|
| 58 |
Emerging Clinical Candidates From the CHDI Pipeline
|
Pacifici, Robert
|
|
|
5 |
2 |
p. 363
|
artikel
|
| 59 |
Experimental therapeutics for dystonia
|
Jinnah, H. A.
|
|
2008
|
5 |
2 |
p. 198-209
|
artikel
|
| 60 |
Experimental Therapeutics for Dystonia
|
Jinnah, H.A.
|
|
2008
|
5 |
2 |
p. 198-209
12 p.
|
artikel
|
| 61 |
Experimental Therapeutics for Dystonia
|
Jinnah, H.A.
|
|
|
5 |
2 |
p. 198-209
|
artikel
|
| 62 |
Experimental Therapeutics for Huntington’s Disease: Challenges and Hurdles to Successful Clinical Development
|
Katz, Russell
|
|
2008
|
5 |
2 |
p. 363-
1 p.
|
artikel
|
| 63 |
Experimental Therapeutics for Huntington’s Disease: Challenges and Hurdles to Successful Clinical Development
|
Katz, Russell
|
|
|
5 |
2 |
p. 363
|
artikel
|
| 64 |
First Report of Huntington’s Disease in West Asian Immigrants Living in the United States
|
Tempkin, T.
|
|
2008
|
5 |
2 |
p. 364-
1 p.
|
artikel
|
| 65 |
First Report of Huntington’s Disease in West Asian Immigrants Living in the United States
|
Tempkin, T.
|
|
|
5 |
2 |
p. 364
|
artikel
|
| 66 |
Five Years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study)
|
Kayson, E.P.
|
|
2008
|
5 |
2 |
p. 366-
1 p.
|
artikel
|
| 67 |
Five Years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study)
|
Kayson, E.P.
|
|
|
5 |
2 |
p. 366
|
artikel
|
| 68 |
Genetic Testing for the Huntingtin Gene CAG Repeat Comparing DNA from Buccal Swabs with DNA from Peripheral Blood
|
Wasserman, L.
|
|
2008
|
5 |
2 |
p. 374-
1 p.
|
artikel
|
| 69 |
Genetic Testing for the Huntingtin Gene CAG Repeat Comparing DNA from Buccal Swabs with DNA from Peripheral Blood
|
Wasserman, L.
|
|
|
5 |
2 |
p. 374
|
artikel
|
| 70 |
HD Repeat Determines the Rate of Neuropathological Change
|
Massood, T.
|
|
2008
|
5 |
2 |
p. 367-
1 p.
|
artikel
|
| 71 |
HD Repeat Determines the Rate of Neuropathological Change
|
Massood, T.
|
|
|
5 |
2 |
p. 367
|
artikel
|
| 72 |
HD Unmet Clinical Research Needs: Perspective From the Pre-Manifest HD Population
|
Moser, Katharine
|
|
2008
|
5 |
2 |
p. 362-
1 p.
|
artikel
|
| 73 |
HD Unmet Clinical Research Needs: Perspective From the Pre-Manifest HD Population
|
Moser, Katharine
|
|
|
5 |
2 |
p. 362
|
artikel
|
| 74 |
How People With Huntington’s Disease Die: A Survey
|
Lechich, A.J.
|
|
2008
|
5 |
2 |
p. 370-
1 p.
|
artikel
|
| 75 |
How People With Huntington’s Disease Die: A Survey
|
Lechich, A.J.
|
|
|
5 |
2 |
p. 370
|
artikel
|
| 76 |
Huntington’s Disease: Causes and Place of Death in a Closely Followed Population
|
McCusker, E.A.
|
|
2008
|
5 |
2 |
p. 370-
1 p.
|
artikel
|
| 77 |
Huntington’s Disease: Causes and Place of Death in a Closely Followed Population
|
McCusker, E.A.
|
|
|
5 |
2 |
p. 370
|
artikel
|
| 78 |
Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group
|
Moser, Katharine
|
|
2008
|
5 |
2 |
p. 362-375
|
artikel
|
| 79 |
Influence of Insurance on the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington’s Disease
|
Oster, E.
|
|
2008
|
5 |
2 |
p. 368-
1 p.
|
artikel
|
| 80 |
Influence of Insurance on the Decision to Pursue Genetic Testing in Individuals at Risk for Huntington’s Disease
|
Oster, E.
|
|
|
5 |
2 |
p. 368
|
artikel
|
| 81 |
Item Reduction of the University of Pennsylvania Smell Identification Test: Preparation for Clinical Trials in Pre-HD using the PREDICT-HD Cohort
|
Whitlock, K.B.
|
|
2008
|
5 |
2 |
p. 372-
1 p.
|
artikel
|
| 82 |
Item Reduction of the University of Pennsylvania Smell Identification Test: Preparation for Clinical Trials in Pre-HD using the PREDICT-HD Cohort
|
Whitlock, K.B.
|
|
|
5 |
2 |
p. 372
|
artikel
|
| 83 |
Late-Onset Huntington’s Disease: A Review of 41 Cases
|
Lipe, H.
|
|
2008
|
5 |
2 |
p. 370-
1 p.
|
artikel
|
| 84 |
Late-Onset Huntington’s Disease: A Review of 41 Cases
|
Lipe, H.
|
|
|
5 |
2 |
p. 370
|
artikel
|
| 85 |
Living at Risk: Concealing Risk and Preserving Hope in Huntington’s Disease
|
Quaid, K.
|
|
2008
|
5 |
2 |
p. 368-369
2 p.
|
artikel
|
| 86 |
Living at Risk: Concealing Risk and Preserving Hope in Huntington’s Disease
|
Quaid, K.
|
|
|
5 |
2 |
p. 368-369
|
artikel
|
| 87 |
Longitudinal Decline in Negative Emotion Recognition Prior to Diagnosis in Huntington’s Disease
|
Johnson, S.A.
|
|
2008
|
5 |
2 |
p. 369-
1 p.
|
artikel
|
| 88 |
Longitudinal Decline in Negative Emotion Recognition Prior to Diagnosis in Huntington’s Disease
|
Johnson, S.A.
|
|
|
5 |
2 |
p. 369
|
artikel
|
| 89 |
Long-Term Effects of Olanzapine on Motor Features and Weight in Huntington’s Disease
|
Wheelock, V.
|
|
2008
|
5 |
2 |
p. 365-
1 p.
|
artikel
|
| 90 |
Long-Term Effects of Olanzapine on Motor Features and Weight in Huntington’s Disease
|
Wheelock, V.
|
|
|
5 |
2 |
p. 365
|
artikel
|
| 91 |
Long-Term Treatment with Olanzapine and Risperidone in Relation to Dystonia in Huntington’s Disease
|
Young, P.
|
|
2008
|
5 |
2 |
p. 364-365
2 p.
|
artikel
|
| 92 |
Long-Term Treatment with Olanzapine and Risperidone in Relation to Dystonia in Huntington’s Disease
|
Young, P.
|
|
|
5 |
2 |
p. 364-365
|
artikel
|
| 93 |
Mechanisms and targets of deep brain stimulation in movement disorders
|
Johnson, Matthew D.
|
|
2008
|
5 |
2 |
p. 294-308
|
artikel
|
| 94 |
Mechanisms and Targets of Deep Brain Stimulation in Movement Disorders
|
Johnson, Matthew D.
|
|
2008
|
5 |
2 |
p. 294-308
15 p.
|
artikel
|
| 95 |
Mechanisms and Targets of Deep Brain Stimulation in Movement Disorders
|
Johnson, Matthew D.
|
|
|
5 |
2 |
p. 294-308
|
artikel
|
| 96 |
Neuroprotection for Huntington’s disease: Ready, set, slow
|
Hersch, Steven M.
|
|
2008
|
5 |
2 |
p. 226-236
|
artikel
|
| 97 |
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
|
Hersch, Steven M.
|
|
2008
|
5 |
2 |
p. 226-236
11 p.
|
artikel
|
| 98 |
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
|
Hersch, Steven M.
|
|
|
5 |
2 |
p. 226-236
|
artikel
|
| 99 |
Noninvasive brain stimulation for Parkinson’s disease and dystonia
|
Wu, Allan D.
|
|
2008
|
5 |
2 |
p. 345-361
|
artikel
|
| 100 |
Noninvasive Brain Stimulation for Parkinson’s Disease and Dystonia
|
Wu, Allan D.
|
|
2008
|
5 |
2 |
p. 345-361
17 p.
|
artikel
|
| 101 |
Noninvasive Brain Stimulation for Parkinson’s Disease and Dystonia
|
Wu, Allan D.
|
|
|
5 |
2 |
p. 345-361
|
artikel
|
| 102 |
Optimal Measurement of Clinical and Biological Markers for Clinical Trials: The HD Toolkit Project
|
Stout, J.C.
|
|
2008
|
5 |
2 |
p. 362-363
2 p.
|
artikel
|
| 103 |
Optimal Measurement of Clinical and Biological Markers for Clinical Trials: The HD Toolkit Project
|
Stout, J.C.
|
|
|
5 |
2 |
p. 362-363
|
artikel
|
| 104 |
PHEND-HD: A Safety, Tolerability, and Biomarker Study of Phenylbutyrate in Symptomatic HD
|
Hersch, S.
|
|
2008
|
5 |
2 |
p. 363-
1 p.
|
artikel
|
| 105 |
PHEND-HD: A Safety, Tolerability, and Biomarker Study of Phenylbutyrate in Symptomatic HD
|
Hersch, S.
|
|
|
5 |
2 |
p. 363
|
artikel
|
| 106 |
Plasma 8-OH2′dG As a Diagnostic and Pharmacodynamic Biomarker for HD
|
Hersch, S.
|
|
2008
|
5 |
2 |
p. 367-
1 p.
|
artikel
|
| 107 |
Plasma 8-OH2′dG As a Diagnostic and Pharmacodynamic Biomarker for HD
|
Hersch, S.
|
|
|
5 |
2 |
p. 367
|
artikel
|
| 108 |
Poster viewing
|
|
|
2008
|
5 |
2 |
p. 362-
1 p.
|
artikel
|
| 109 |
Poster viewing
|
|
|
|
5 |
2 |
p. 362
|
artikel
|
| 110 |
PREDICT-HD Family Participation in HSG Site 144
|
Yastrubetskaya, O.
|
|
2008
|
5 |
2 |
p. 368-
1 p.
|
artikel
|
| 111 |
PREDICT-HD Family Participation in HSG Site 144
|
Yastrubetskaya, O.
|
|
|
5 |
2 |
p. 368
|
artikel
|
| 112 |
Predictive Value of CAG Repeat Length for HD Onset: Effects of Ethnicity, Demographic, and Clinical Variables
|
Kane, A.E.
|
|
2008
|
5 |
2 |
p. 365-366
2 p.
|
artikel
|
| 113 |
Predictive Value of CAG Repeat Length for HD Onset: Effects of Ethnicity, Demographic, and Clinical Variables
|
Kane, A.E.
|
|
|
5 |
2 |
p. 365-366
|
artikel
|
| 114 |
Proposed Criteria for the Diagnosis of Dementia Associated With Huntington’s Disease (HD)
|
Peavy, G.M.
|
|
2008
|
5 |
2 |
p. 373-
1 p.
|
artikel
|
| 115 |
Proposed Criteria for the Diagnosis of Dementia Associated With Huntington’s Disease (HD)
|
Peavy, G.M.
|
|
|
5 |
2 |
p. 373
|
artikel
|
| 116 |
Protection against Parkinson’s disease progression: Clinical experience
|
LeWitt, Peter A.
|
|
2008
|
5 |
2 |
p. 210-225
|
artikel
|
| 117 |
Protection Against Parkinson’s Disease Progression: Clinical Experience
|
LeWitt, Peter A.
|
|
2008
|
5 |
2 |
p. 210-225
16 p.
|
artikel
|
| 118 |
Protection Against Parkinson’s Disease Progression: Clinical Experience
|
LeWitt, Peter A.
|
|
|
5 |
2 |
p. 210-225
|
artikel
|
| 119 |
Recruitment and Retention Strategies for PREDICT-HD Study at HSG Site 144
|
Yastrubetskaya, O.
|
|
2008
|
5 |
2 |
p. 368-
1 p.
|
artikel
|
| 120 |
Recruitment and Retention Strategies for PREDICT-HD Study at HSG Site 144
|
Yastrubetskaya, O.
|
|
|
5 |
2 |
p. 368
|
artikel
|
| 121 |
SCA2 Mimicking Juvenile Onset HD: A Case Report
|
Schwartz, G.
|
|
2008
|
5 |
2 |
p. 364-
1 p.
|
artikel
|
| 122 |
SCA2 Mimicking Juvenile Onset HD: A Case Report
|
Schwartz, G.
|
|
|
5 |
2 |
p. 364
|
artikel
|
| 123 |
Sensitivity of the UHDRS Cognitive Tests in Pre-Diagnosis and Early Huntington’s Disease (HD)
|
Tomusk, A.
|
|
2008
|
5 |
2 |
p. 369-
1 p.
|
artikel
|
| 124 |
Sensitivity of the UHDRS Cognitive Tests in Pre-Diagnosis and Early Huntington’s Disease (HD)
|
Tomusk, A.
|
|
|
5 |
2 |
p. 369
|
artikel
|
| 125 |
Spheramine for treatment of Parkinson’s disease
|
Stover, Natividad P.
|
|
2008
|
5 |
2 |
p. 252-259
|
artikel
|
| 126 |
Spheramine for Treatment of Parkinson’s Disease
|
Stover, Natividad P.
|
|
2008
|
5 |
2 |
p. 252-259
8 p.
|
artikel
|
| 127 |
Spheramine for Treatment of Parkinson’s Disease
|
Stover, Natividad P.
|
|
|
5 |
2 |
p. 252-259
|
artikel
|
| 128 |
Subtle Motor Abnormalities in Pre-Manifest HD Are Associated With Gene Status, Probability of Disease Onset, and Striatal Atrophy
|
Biglan, K.M.
|
|
2008
|
5 |
2 |
p. 362-
1 p.
|
artikel
|
| 129 |
Subtle Motor Abnormalities in Pre-Manifest HD Are Associated With Gene Status, Probability of Disease Onset, and Striatal Atrophy
|
Biglan, K.M.
|
|
|
5 |
2 |
p. 362
|
artikel
|
| 130 |
Symptomatic treatment of Huntington disease
|
Adam, Octavian R.
|
|
2008
|
5 |
2 |
p. 181-197
|
artikel
|
| 131 |
Symptomatic Treatment of Huntington Disease
|
Adam, Octavian R.
|
|
2008
|
5 |
2 |
p. 181-197
17 p.
|
artikel
|
| 132 |
Symptomatic Treatment of Huntington Disease
|
Adam, Octavian R.
|
|
|
5 |
2 |
p. 181-197
|
artikel
|
| 133 |
The MLK Inhibitor, CEP-1347, Suppresses Mutant Huntingtin-Associated Neurotoxicity in Cell, Drosophila and Mouse Models of HD by Modulating MAPK Signaling and Upregulating Brain Derived Neurotrophic Factor
|
Apostol, B.L.
|
|
2008
|
5 |
2 |
p. 371-
1 p.
|
artikel
|
| 134 |
The MLK Inhibitor, CEP-1347, Suppresses Mutant Huntingtin-Associated Neurotoxicity in Cell, Drosophila and Mouse Models of HD by Modulating MAPK Signaling and Upregulating Brain Derived Neurotrophic Factor
|
Apostol, B.L.
|
|
|
5 |
2 |
p. 371
|
artikel
|
| 135 |
Therapeutic potentials of human embryonic stem cells in Parkinson’s disease
|
Newman, Mary B.
|
|
2008
|
5 |
2 |
p. 237-251
|
artikel
|
| 136 |
Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson’s Disease
|
Newman, Mary B.
|
|
2008
|
5 |
2 |
p. 237-251
15 p.
|
artikel
|
| 137 |
Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson’s Disease
|
Newman, Mary B.
|
|
|
5 |
2 |
p. 237-251
|
artikel
|
| 138 |
Treatment of dystonia with deep brain stimulation
|
Ostrem, Jill L.
|
|
2008
|
5 |
2 |
p. 320-330
|
artikel
|
| 139 |
Treatment of Dystonia with Deep Brain Stimulation
|
Ostrem, Jill L.
|
|
2008
|
5 |
2 |
p. 320-330
11 p.
|
artikel
|
| 140 |
Treatment of Dystonia with Deep Brain Stimulation
|
Ostrem, Jill L.
|
|
|
5 |
2 |
p. 320-330
|
artikel
|
| 141 |
Treatment of HD: A Survey of HD Clinicians
|
Veatch Goodman, L.
|
|
2008
|
5 |
2 |
p. 374-
1 p.
|
artikel
|
| 142 |
Treatment of HD: A Survey of HD Clinicians
|
Veatch Goodman, L.
|
|
|
5 |
2 |
p. 374
|
artikel
|
| 143 |
Treatment of Parkinson’s disease with trophic factors
|
Peterson, Amie L.
|
|
2008
|
5 |
2 |
p. 270-280
|
artikel
|
| 144 |
Treatment of Parkinson’s Disease with Trophic Factors
|
Peterson, Amie L.
|
|
2008
|
5 |
2 |
p. 270-280
11 p.
|
artikel
|
| 145 |
Treatment of Parkinson’s Disease with Trophic Factors
|
Peterson, Amie L.
|
|
|
5 |
2 |
p. 270-280
|
artikel
|
| 146 |
What happened to posteroventral pallidotomy for Parkinson’s disease and dystonia?
|
Gross, Robert E.
|
|
2008
|
5 |
2 |
p. 281-293
|
artikel
|
| 147 |
What Happened to Posteroventral Pallidotomy for Parkinson’s Disease and Dystonia?
|
Gross, Robert E.
|
|
2008
|
5 |
2 |
p. 281-293
13 p.
|
artikel
|
| 148 |
What Happened to Posteroventral Pallidotomy for Parkinson’s Disease and Dystonia?
|
Gross, Robert E.
|
|
|
5 |
2 |
p. 281-293
|
artikel
|
Tijdschrift beschrijving